BioSpace News Archive

Investment marks a significant funding commitment to homelessness prevention

Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other neurological disorders today announced a partnership with BrainScope for use of their FDA-cleared BrainScope One device in Prevacus’ upcoming Phase 1b clinical research study as an objective biomarker of brain function

The National Institutes of Health (NIH) has awarded EpiVax, Inc. (“EpiVax”), experts in the field of immunogenicity risk assessment, a $324,980 Small Business Innovation Research (SBIR) grant.

Precision Biologics will present data at the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland, May 20-24. Recognizing the need to improve Factor VIII (FVIII) inhibitor testing for people with...

New indications greatly increase the treatment possibilities of this innovative therapy, which has rapidly become the standard of care for bladder cancer treatment at major medical institutions across the United States.

Founders along with members of management will ring the opening bell at the New York Stock Exchange this morning at 9:30 a.m. ET.

They’ll evaluate the efficacy of seladelpar in a randomized, double-blind, placebo-controlled, multi-center Phase 2b study of 175 subjects with biopsy-confirmed Nonalcoholic Steatohepatitis (NASH).

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the Bio-Plex Pro Human Cytokine Screening Panel, the first validated high-performance multiplex assay on the market.

GTx, Inc. (Nasdaq: GTXI) today released additional data supporting the durability of the response to a 12-week treatment with enobosarm 3 mg in an open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm in postmenopausal women with stress urinary incontinence (SUI)...

More than 220,000 people will be diagnosed with lung cancer in 2018. Nearly 160,000 people will die from the disease -- more than from breast, colon and prostate cancers combined. This exam is the first and only cost-effective test proven to significantly reduce lung cancer deaths.